Aridis Pharmaceuticals Inc. (ARDS)
| Market Cap | 58.07M |
| Revenue (ttm) | 1,000,000 |
| Net Income (ttm) | -23.71M |
| Shares Out | 11.23M |
| EPS (ttm) | -2.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $5.17 |
| Previous Close | $5.85 |
| Change ($) | -0.68 |
| Change (%) | -11.62% |
| Day's Open | 5.80 |
| Day's Range | 4.98 - 7.69 |
| Day's Volume | 4,513,696 |
| 52-Week Range | 4.70 - 8.50 |
LOS GATOS, Calif., July 19, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (LSE/ST...
Aridis Pharmaceuticals' (ARDS) inhaled COVID-19 dual antibody cocktail treatment, AR-712, binds and neutralizes the Delta variant of the virus. Stock rises in after-hours trading.
Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has announced that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant of COVID-19 at a highly effective level (~20ng/mL). Binding analyse...
LOS GATOS, Calif., July 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...
ARIDIS PHARMACT (ARDS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more stren...
LOS GATOS, Calif., May 11, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...
PARAMUS, N.J.--(BUSINESS WIRE)--Kermode Biotechnologies, Inc., announced that it is actively engaged in discovery to identify the mode of transmission and replication for the ASFV.
PARAMUS, N.J.--(BUSINESS WIRE)--Kermode Biotechnologies, Inc., announced that it is actively engaged in discovery to identify the mode of transmission and replication for the ASFV.
LOS GATOS, Calif., March 30, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to t...
LOS GATOS, Calif., March 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to t...
Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has entered into an out-licensing and product discovery agreement with a privately-held Kermode Biotechnologies Inc. Kermode works on vaccines and mAbs for zoon...
Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has added its inhaled AR-711 monoclonal antibody with a second antibody, AR-713, designed to neutralize newly emerging COVID-19 mutated variants. The company sa...
LOS GATOS, Calif., Feb. 23, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...
SAN JOSE, Calif., Nov. 24, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...
SAN JOSE, Calif., Nov. 20, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...
SAN JOSE, Calif., Oct. 19, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...
SAN JOSE, Calif., Oct. 14, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company"), a biopharmaceutical company focused on the discovery and development of novel anti-infective ...
SAN JOSE, Calif., Sept. 8, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc.
SAN JOSE, Calif., Sept. 4, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc.
SAN JOSE, Calif., Aug. 11, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc.
SAN JOSE, Calif., June 26, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...
SAN JOSE, Calif., June 22, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...
SAN JOSE, Calif., June 15, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...
As of late, it has definitely been a great time to be an investor Aridis Pharmaceuticals
Shares of the thinly traded, micro-cap biotech Aridis Pharmaceuticals Inc (NASDAQ: ARDS) were retreating to a one-week low Tuesday morning.
Shares of Aridis Pharmaceuticals Inc. plunged 27% to pace all premarket decliners Tuesday, after the biopharmaceutical company said a phase 2 trial of its treatment of ventilator-associated pneumonia (A...
Aridis Pharmaceuticals has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
About ARDS
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginos... [Read more...]
| Industry Biotechnology | IPO Date Aug 10, 2018 |
| Stock Exchange NASDAQ | Ticker Symbol ARDS |
Financial Performance
In 2020, ARDS's revenue was $1,000,000, a decrease of -2.15% compared to the previous year's $1.02 million. Losses were -$22.33 million, -24.76% less than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for ARDS stock is "Buy." The 12-month stock price forecast is 17.00, which is an increase of 228.82% from the latest price.